Latest Period
Q4 2025
Security Snapshot
Applied Therapeutics, Inc. - Common Stock, par value $0.0001 per share (APLT) Institutional Ownership
CUSIP: 03828A101
13F Institutional Holders and Ownership History from Q2 2019 to Q1 2026
Institutions Reporting
50
Shares (Excl. Options)
58,883,039
Price
$0.10
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- APLT
- Shares outstanding
- 143,223,667
- Price per share
- $0.10
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 58,883,039
- Total reported value
- $5,929,909
- % of total 13F portfolios
- 0%
- Share change
- -35,826,681
- Value change
- -$23,764,068
- Number of holders
- 50
- Price from insider filings
- $0.10
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- APLT - Applied Therapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 03828A101.
- 50 institutions reported positions in Q4 2025.
- 12 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 50 to 0 between Q4 2025 and Q1 2026.
- Reported value moved from $5,929,909 to $0.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 50 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 03828A101?
CUSIP 03828A101 identifies APLT - Applied Therapeutics, Inc. - Common Stock, par value $0.0001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 03828A101:
Significant Owners of Applied Therapeutics, Inc. - Common Stock, par value $0.0001 per share (APLT) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 15% | +13% | $12,946,856 | +$1,644,911 | 21,403,300 | +15% | T. Rowe Price Investment Management, Inc. | 30 Sep 2025 |
| Alyeska Investment Group, L.P. | 5.8% | $2,615,924 | 6,707,497 | Alyeska Investment Group, L.P. | 31 Dec 2024 | |||
| ALEXANDRIA REAL ESTATE EQUITIES, INC. | 4.3% | $1,755,000 | 6,500,000 | Alexandria Real Estate Equities, Inc. | 11 Dec 2025 | |||
| Propel Bio Management, LLC | 4.2% | $1,564,002 | 6,015,394 | Propel Bio Management, LLC | 29 Dec 2025 | |||
| Venrock Healthcare Capital Partners III, L.P. | 4.1% | -58% | $2,171,407 | -$2,432,661 | 5,567,709 | -53% | Venrock Healthcare Capital Partners III, L.P. | 31 Mar 2025 |
| BlackRock, Inc. | 3.7% | -54% | $1,003,183 | -$783,523 | 5,219,475 | -44% | BlackRock, Inc. | 30 Jun 2025 |
| VANGUARD GROUP INC | 3.3% | -34% | $1,473,225 | -$359,492 | 4,734,013 | -20% | The Vanguard Group | 30 Jun 2025 |
| Schonfeld Strategic Advisors LLC | 3.3% | -53% | $1,823,678 | -$1,596,482 | 4,676,097 | -47% | Schonfeld Strategic Advisors LLC | 31 Mar 2025 |
| PERCEPTIVE ADVISORS LLC | 2.4% | $1,115,400 | 2,860,000 | Perceptive Advisors LLC | 31 Dec 2024 | |||
| MORGAN STANLEY | 2.5% | -64% | $1,114,983 | -$2,323,072 | 2,858,931 | -68% | Morgan Stanley | 31 Jan 2025 |
| FRANKLIN RESOURCES INC | 1.7% | -70% | $781,326 | -$1,871,029 | 2,003,400 | -71% | Franklin Resources, Inc. | 31 Dec 2024 |
| JANUS HENDERSON GROUP PLC | 0% | -104% | $13,958 | -$4,706,957 | 35,791 | -100% | JANUS HENDERSON GROUP PLC | 31 Dec 2024 |
As of 31 Dec 2025, 50 institutional investors reported holding 58,883,039 shares of Applied Therapeutics, Inc. - Common Stock, par value $0.0001 per share (APLT). This represents 41% of the company’s total 143,223,667 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Applied Therapeutics, Inc. - Common Stock, par value $0.0001 per share (APLT) together control 40% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 15% | 21,747,844 | +1.6% | 0% | $2,175,000 |
| VANGUARD GROUP INC | 4.4% | 6,353,018 | +25% | 0% | $635,302 |
| Knoll Capital Management, LLC | 4.2% | 6,050,000 | -22% | 0.28% | $605,000 |
| DELTEC ASSET MANAGEMENT LLC | 2.7% | 3,847,449 | 0.06% | $384,745 | |
| BlackRock, Inc. | 2.3% | 3,251,462 | -15% | 0% | $325,146 |
| RENAISSANCE TECHNOLOGIES LLC | 1.9% | 2,706,156 | 0% | $270,616 | |
| Pathstone Holdings, LLC | 1.8% | 2,643,540 | 0% | 0% | $305,065 |
| JANE STREET GROUP, LLC | 1.5% | 2,087,404 | 0% | $208,740 | |
| GEODE CAPITAL MANAGEMENT, LLC | 1% | 1,492,903 | +17% | 0% | $149,330 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 0.85% | 1,211,629 | -45% | 0% | $121,163 |
| MILLENNIUM MANAGEMENT LLC | 0.73% | 1,051,846 | -45% | 0% | $105,185 |
| UBS Group AG | 0.5% | 718,924 | -62% | 0% | $71,892 |
| DEUTSCHE BANK AG\ | 0.43% | 622,226 | 0% | 0% | $62,223 |
| Graham Capital Management, L.P. | 0.4% | 572,759 | 0% | $57,276 | |
| STATE STREET CORP | 0.39% | 558,178 | +7.6% | 0% | $55,818 |
| Virtu Financial LLC | 0.35% | 496,288 | +873% | 0% | $50,000 |
| Lynx1 Capital Management LP | 0.29% | 410,500 | 0.01% | $41,050 | |
| MARSHALL WACE, LLP | 0.24% | 337,389 | -87% | 0% | $33,739 |
| Hennion & Walsh Asset Management, Inc. | 0.23% | 327,137 | +16% | 0% | $32,714 |
| EQUITEC PROPRIETARY MARKETS, LLC | 0.21% | 300,600 | 0.14% | $30,060 | |
| Bank of New York Mellon Corp | 0.18% | 253,573 | +219% | 0% | $25,357 |
| NORTHERN TRUST CORP | 0.17% | 245,144 | +41% | 0% | $24,514 |
| Rockefeller Capital Management L.P. | 0.17% | 241,897 | -38% | 0% | $24,190 |
| GTS SECURITIES LLC | 0.14% | 200,009 | 0% | $20,001 | |
| MORGAN STANLEY | 0.12% | 178,474 | -75% | 0% | $17,847 |
Institutional Holders of Applied Therapeutics, Inc. - Common Stock, par value $0.0001 per share (APLT) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 0 | $0 | -$1,951,806 | $0.10 | 0 |
| 2025 Q4 | 58,883,039 | $5,929,909 | -$23,764,068 | $0.10 | 50 |
| 2025 Q3 | 94,763,328 | $57,199,408 | +$5,274,176 | $0.60 | 69 |
| 2025 Q2 | 88,058,885 | $27,371,087 | -$7,459,469 | $0.31 | 72 |
| 2025 Q1 | 106,044,815 | $51,845,704 | -$6,334,916 | $0.49 | 89 |
| 2024 Q4 | 115,065,005 | $98,537,797 | -$63,025,089 | $0.86 | 116 |
| 2024 Q3 | 112,721,874 | $960,819,113 | +$78,176,113 | $8.50 | 125 |
| 2024 Q2 | 103,226,978 | $481,702,267 | +$36,985,908 | $4.67 | 92 |
| 2024 Q1 | 93,958,967 | $638,614,949 | +$241,302,453 | $6.80 | 88 |
| 2023 Q4 | 61,449,532 | $205,844,085 | +$29,840,415 | $3.35 | 83 |
| 2023 Q3 | 42,970,428 | $106,996,842 | +$29,101,733 | $2.49 | 54 |
| 2023 Q2 | 31,465,661 | $40,275,555 | +$15,796,729 | $1.28 | 38 |
| 2023 Q1 | 19,276,965 | $15,634,509 | -$232,317 | $0.81 | 34 |
| 2022 Q4 | 19,679,561 | $15,064,959 | -$2,201,503 | $0.76 | 37 |
| 2022 Q3 | 22,671,560 | $21,085,673 | -$3,749,758 | $0.93 | 38 |
| 2022 Q2 | 26,706,667 | $25,318,845 | +$12,989,524 | $0.95 | 46 |
| 2022 Q1 | 12,347,239 | $26,037,310 | -$34,487,329 | $2.11 | 68 |
| 2021 Q4 | 14,922,342 | $133,548,279 | -$7,772,547 | $8.95 | 67 |
| 2021 Q3 | 15,108,904 | $250,903,236 | -$6,255,939 | $16.60 | 66 |
| 2021 Q2 | 15,367,633 | $319,342,764 | +$10,194,603 | $20.78 | 68 |
| 2021 Q1 | 14,854,223 | $278,593,752 | +$51,374,327 | $18.76 | 66 |
| 2020 Q4 | 12,104,777 | $266,428,658 | -$1,610,604 | $22.01 | 67 |
| 2020 Q3 | 12,195,771 | $253,182,315 | -$6,258,655 | $20.76 | 66 |
| 2020 Q2 | 11,427,491 | $412,583,649 | +$78,213,106 | $36.15 | 71 |
| 2020 Q1 | 9,645,977 | $315,329,165 | +$155,281,170 | $32.69 | 62 |
| 2019 Q4 | 4,991,742 | $136,175,281 | +$71,201,517 | $27.28 | 45 |
| 2019 Q3 | 2,395,520 | $26,326,659 | +$2,265,568 | $10.99 | 29 |
| 2019 Q2 | 2,195,975 | $18,095,000 | +$18,095,000 | $8.24 | 13 |